Diabetic Macular Edema
ICo Therapeutics receives U.S. FDA clearance to initiate trial in diabetic macular edema
Published in Obesity and Diabetes Week, February 19th, 2007
"The success of our IND application brings iCo one step closer to creating an effective treatment for diabetic macular edema," said Andrew Rae, president and CEO of iCo Therapeutics.
Designed and discovered by Isis Pharmaceuticals Inc., iCo-007 is a second-generation antisense drug that targets c-Raf kinase messenger RNA. ICo-007 is expected to decrease the edema in the retina by decreasing the signaling of various growth factors such as VEGF that signal...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
More Articles from Obesity and Diabetes Week
- Obesity Research
Protein proves to be major link in brain-obesity puzzle - Obesity and Diabetes
Harokopio University reports research in obesity and diabetes in children - Obesity and Diabetes
King's College London details research in obesity and diabetes - Obesity and Diabetes
New obesity and diabetes data have been reported by researchers at Korea Institute of Oriental Medicine - Obesity and Diabetes
New obesity and diabetes data have been reported by scientists at Yonsei University, Genome Center - Obesity and Diabetes
New obesity and diabetes research reported from Institute of Biomedical Technologies - More from this issue of Obesity and Diabetes Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
